<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Pro12Ala polymorphism of the gene encoding the peroxisome proliferator-activated receptor (PPAR)-gamma2 has recently been shown to be associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present analysis, we investigated whether PPAR-gamma2 Pro12Ala was associated with microvascular complications of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, such as <z:mp ids='MP_0002871'>albuminuria</z:mp>, <z:hpo ids='HP_0003774'>end-stage renal failure</z:hpo> (ESRF), or <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 445 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who were enrolled in the Berlin <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo> Study and in whom we determined <z:mp ids='MP_0002871'>albuminuria</z:mp> and the presence of ESRF and <z:hpo ids='HP_0000488'>retinopathy</z:hpo> were genotyped for the PPAR-gamma2 Pro12Ala polymorphism </plain></SENT>
<SENT sid="3" pm="."><plain>We also measured potentially important covariables, such as blood pressure, BMI, duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, and serum <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Among 445 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (mean age 59.3 years), the Pro12Ala genotype distribution was in Hardy-Weinberg equilibrium (P = 0.42) </plain></SENT>
<SENT sid="5" pm="."><plain>The Ala12 allele frequency was 0.14 </plain></SENT>
<SENT sid="6" pm="."><plain>With adjustment for covariables, the 118 Ala12 allele carriers had significantly lower urinary albumin excretion (UAE) than the 327 noncarriers (17.1 vs. 25.8 mg/d; P = 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>The percentage decrease in UAE observed in PPAR-gamma Ala12 allele carriers relative to noncarriers (P = 0.003) rose from 0.2% (P = 0.99) to 54% (P = 0.008) and to 70% (P = 0.01) when the duration of <z:mp ids='MP_0002055'>diabetes</z:mp> increased from &lt;10 years to 10-19 years and to &gt;or=20 years, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Similarly, the odds ratios of having <z:mp ids='MP_0002871'>albuminuria</z:mp> decreased from 1.22 (P = 0.54) to 0.61 (P = 0.23) and to 0.11 (P = 0.007), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, PPAR-gamma2 Ala12 allele carriers had significantly lower UAE and tended to develop overt <z:hpo ids='HP_0000093'>proteinuria</z:hpo> less frequently </plain></SENT>
<SENT sid="10" pm="."><plain>These observations suggest a protective effect of the Ala12 allele in relation to diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>